Trial Profile
A Phase I Single-Dose Open-Label Study Determining The Absolute Bioavailability Of Oral Rolapitant By Using An Intravenous Microdose Of [14C]-Rolapitant In Healthy Volunteers: Absolute Bioavailability Study.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Feb 2017
Price :
$35
*
At a glance
- Drugs Rolapitant (Primary) ; Rolapitant (Primary)
- Indications Chemotherapy-induced nausea and vomiting
- Focus Pharmacokinetics
- Sponsors TESARO
- 10 Feb 2017 New trial record
- 31 Jan 2017 Results published in the Clinical Pharmacology and Therapeutics journal.